FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281934510> ?p ?o ?g. }

• W4281934510 endingPage "e18749" @default.
• W4281934510 startingPage "e18749" @default.
• W4281934510 abstract "e18749 Background: Biosimilar adoption offers the potential to save significant cost while maintaining high quality of care. The Oncology Care Model (OCM) is structured to reward practices for decreasing total cost of care (TCOC) compared to historical baseline prices that are adjusted by a trend factor accounting for the rising cost of oncology care. Practices are rewarded for bending the cost curve by utilizing lower cost medications. Biosimilar options were introduced for 3 mainstay therapeutic classes in oncology, bevacizumab and trastuzumab in 2019, and rituximab in 2020. This led to a concerted approach for biosimilar adoption in The US Oncology Network (The Network) as an opportunity to reduce TCOC. Here we describe utilization and the financial impact of biosimilar adoption in The Network during OCM performance period 8 (PP8) which enrolled patients from 1/2/2020 to 7/1/2020. Methods: Claims data for the 14 US Oncology Network practices participating in the OCM were used to determine biosimilar utilization for bevacizumab, trastuzumab, and rituximab therapeutic classes. The impact of biosimilar utilization on TCOC was measured by comparing the cost of each dose of a biosimilar vs the estimated cost if the more expensive innovator agent had been used instead. Results: Biosimilar utilization increased for each therapeutic class from prior performance periods. Biosimilar use for bevacizumab was 0% in PP6, 5% in PP7 and 43% in PP8. For trastuzumab, utilization was 0% in PP6, 4% in PP7 and 33% in PP8. Rituximab biosimilar utilization was 0% in PP6, 2% in PP7 and 41% in PP8. We compared the actual cost of these three medications in our OCM claims in PP8 vs. the calculated cost based on Medicare reimbursement as ASP + 6% minus sequestration if the more expensive innovator drugs had been used entirely. The difference in the actual cost vs estimated cost led to a savings of $6.61 million by using the biosimilars over innovator drugs. Conclusions: The increased utilization of biosimilars in The Network generated significant savings in OCM. Continued adoption of biosimilars will increase savings to Medicare in the Oncology Care Model. We estimate that 100% Network adoption of these three biosimilars could save nearly 1.5% of the TCOC in our Network compared to continued use of innovator drugs." @default.
• W4281934510 created "2022-06-13" @default.
• W4281934510 creator A5013296424 @default.
• W4281934510 creator A5038469184 @default.
• W4281934510 creator A5042661691 @default.
• W4281934510 creator A5050311917 @default.
• W4281934510 creator A5052874782 @default.
• W4281934510 creator A5061945633 @default.
• W4281934510 creator A5083503787 @default.
• W4281934510 date "2022-06-01" @default.
• W4281934510 modified "2023-10-03" @default.
• W4281934510 title "Financial impact of biosimilar adoption in the oncology care model for the U.S. Oncology Network." @default.
• W4281934510 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.e18749" @default.
• W4281934510 hasPublicationYear "2022" @default.
• W4281934510 type Work @default.
• W4281934510 citedByCount "0" @default.
• W4281934510 crossrefType "journal-article" @default.
• W4281934510 hasAuthorship W4281934510A5013296424 @default.
• W4281934510 hasAuthorship W4281934510A5038469184 @default.
• W4281934510 hasAuthorship W4281934510A5042661691 @default.
• W4281934510 hasAuthorship W4281934510A5050311917 @default.
• W4281934510 hasAuthorship W4281934510A5052874782 @default.
• W4281934510 hasAuthorship W4281934510A5061945633 @default.
• W4281934510 hasAuthorship W4281934510A5083503787 @default.
• W4281934510 hasConcept C10138342 @default.
• W4281934510 hasConcept C121608353 @default.
• W4281934510 hasConcept C126322002 @default.
• W4281934510 hasConcept C143998085 @default.
• W4281934510 hasConcept C144133560 @default.
• W4281934510 hasConcept C2776473838 @default.
• W4281934510 hasConcept C2776694085 @default.
• W4281934510 hasConcept C2777802072 @default.
• W4281934510 hasConcept C2779338263 @default.
• W4281934510 hasConcept C2779786085 @default.
• W4281934510 hasConcept C2780653079 @default.
• W4281934510 hasConcept C530470458 @default.
• W4281934510 hasConcept C59491497 @default.
• W4281934510 hasConcept C71924100 @default.
• W4281934510 hasConcept C84309077 @default.
• W4281934510 hasConceptScore W4281934510C10138342 @default.
• W4281934510 hasConceptScore W4281934510C121608353 @default.
• W4281934510 hasConceptScore W4281934510C126322002 @default.
• W4281934510 hasConceptScore W4281934510C143998085 @default.
• W4281934510 hasConceptScore W4281934510C144133560 @default.
• W4281934510 hasConceptScore W4281934510C2776473838 @default.
• W4281934510 hasConceptScore W4281934510C2776694085 @default.
• W4281934510 hasConceptScore W4281934510C2777802072 @default.
• W4281934510 hasConceptScore W4281934510C2779338263 @default.
• W4281934510 hasConceptScore W4281934510C2779786085 @default.
• W4281934510 hasConceptScore W4281934510C2780653079 @default.
• W4281934510 hasConceptScore W4281934510C530470458 @default.
• W4281934510 hasConceptScore W4281934510C59491497 @default.
• W4281934510 hasConceptScore W4281934510C71924100 @default.
• W4281934510 hasConceptScore W4281934510C84309077 @default.
• W4281934510 hasIssue "16_suppl" @default.
• W4281934510 hasLocation W42819345101 @default.
• W4281934510 hasOpenAccess W4281934510 @default.
• W4281934510 hasPrimaryLocation W42819345101 @default.
• W4281934510 hasRelatedWork W2581362677 @default.
• W4281934510 hasRelatedWork W2770118444 @default.
• W4281934510 hasRelatedWork W2934222321 @default.
• W4281934510 hasRelatedWork W3095573000 @default.
• W4281934510 hasRelatedWork W3120515715 @default.
• W4281934510 hasRelatedWork W3159009597 @default.
• W4281934510 hasRelatedWork W3197783092 @default.
• W4281934510 hasRelatedWork W4281934510 @default.
• W4281934510 hasRelatedWork W4283514255 @default.
• W4281934510 hasRelatedWork W4310753276 @default.
• W4281934510 hasVolume "40" @default.
• W4281934510 isParatext "false" @default.
• W4281934510 isRetracted "false" @default.
• W4281934510 workType "article" @default.